Smith Group Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Smith Group Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,010	Closed	-$72K	–	415
2019 Q2	$72K	Hold	1,010	–	–	﹤0.01%	255
2019 Q1	$79K	Sell	1,010 -3,046	-75%	-$231K	﹤0.01%	272
2018 Q4	$343K	Sell	4,056 -160	-4%	-$17.1K	0.01%	210
2018 Q3	$722K	Buy	4,216 +818	+24%	+$123K	0.02%	187
2018 Q2	$439K	Hold	3,398	–	–	0.01%	202
2018 Q1	$350K	Sell	3,398 -2,886	-46%	-$285K	0.01%	211
2017 Q4	$537K	Hold	6,284	–	–	0.02%	205
2017 Q3	$534K	Hold	6,284	–	–	0.02%	211
2017 Q2	$476K	Hold	6,284	–	–	0.01%	218
2017 Q1	$415K	Sell	6,284 -16	-0.3%	-$1.05K	0.01%	199
2016 Q4	$399K	Hold	6,300	–	–	0.01%	201
2016 Q3	$401K	Buy	6,300 +818	+15%	+$60.1K	0.01%	195
2016 Q2	$408K	Sell	5,482 -177	-3%	-$13.1K	0.01%	194
2016 Q1	$378K	Buy	+5,659	New	+$344K	0.01%	175
2014 Q4	–	Sell	-32,251	Closed	-$945K	–	432
2014 Q3	$945K	Sell	32,251 -112	-0.3%	-$3.72K	0.04%	178
2014 Q2	$1.26M	Sell	32,363 -1,252	-4%	-$50.8K	0.05%	173
2014 Q1	$1.41M	Sell	33,615 -264	-0.8%	-$11K	0.05%	169
2013 Q4	$1.11M	Buy	+33,879	New	+$1.1M	0.04%	176

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Smith Group Asset Management's LGND Position: Q3 2019 in Review

Smith Group Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 1,010 shares — an estimated $72K sold.

Smith Group Asset Management first reported a position in LGND in Q4 2013 and held it in 18 quarters. The position peaked at $1.41M in Q1 2014. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

Smith Group Asset Management reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Smith Group Asset Management sold 1,010 Ligand Pharmaceuticals shares in Q3 2019, an estimated $72K.
Smith Group Asset Management first reported a position in Ligand Pharmaceuticals in Q4 2013 and held it in 18 quarters.
Smith Group Asset Management's Ligand Pharmaceuticals position peaked at $1.41M in Q1 2014.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Smith Group Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.